Nova Laboratories has announced the European Commission approval of new Xaluprine oral formulation without the preservative propyl parabens. Supplied from January 2013, revised formulation is indicated for acute lymphoblastic leukaemia ...
Tags: European Commission, new Xaluprine oral formulation, steady absorption